Ebio1 is a subtype-selective activator of the voltage-gated potassium channel KCNQ2 that enhances conductance through a unique twist-to-open mechanism. It induces conformational changes in the S6 helix, increasing channel activity at a saturating voltage (+50 mV).

DDD85646 (IMP-366) is an orally active inhibitor of N-myristoyltransferase(NMT), with an IC50 of 2 nM for Trypanosoma brucei NMT (TbNMT) and 4 nM for human NMT (hNMT). It exhibits a potential for treating human African trypanosomiasis.

DDD85646 (IMP-366) is an orally active inhibitor of N-myristoyltransferase(NMT), with an IC50 of 2 nM for Trypanosoma brucei NMT (TbNMT) and 4 nM for human NMT (hNMT). It exhibits a potential for treating human African trypanosomiasis.

DDD85646 (IMP-366) is an orally active inhibitor of N-myristoyltransferase(NMT), with an IC50 of 2 nM for Trypanosoma brucei NMT (TbNMT) and 4 nM for human NMT (hNMT). It exhibits a potential for treating human African trypanosomiasis.

AZD2389 is a potent, orally active, and selective inhibitor of fibroblast activation protein (FAP) with the potential to treat metabolic dysfunction-associated steatohepatitis.

AZD2389 is a potent, orally active, and selective inhibitor of fibroblast activation protein (FAP) with the potential to treat metabolic dysfunction-associated steatohepatitis.

DDD85646 (IMP-366) is an orally active inhibitor of N-myristoyltransferase(NMT), with an IC50 of 2 nM for Trypanosoma brucei NMT (TbNMT) and 4 nM for human NMT (hNMT). It exhibits a potential for treating human African trypanosomiasis.

AZD2389 is a potent, orally active, and selective inhibitor of fibroblast activation protein (FAP) with the potential to treat metabolic dysfunction-associated steatohepatitis.

AkaLumine hydrochloride is a luciferin analogue, with a Km of 2.06 μM for recombinant firefly luciferase (Fluc) protein. Its near-infrared emission peak enables deep tissue imaging and enhances target-detection sensitivity, allowing more accurate, non-invasive bioluminescence imaging at very low concentrations in animal models.

AZD2389 is a potent, orally active, and selective inhibitor of fibroblast activation protein (FAP) with the potential to treat metabolic dysfunction-associated steatohepatitis.